Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Economic information and modeling reportBudget impact model

Cost assumptions

8 evidence topics · 7 sources

Budget impact model of tovecimig: cost assumptions

No evidence found.

United States drug cost inputs per treatment cycle for regimens used in advanced biliary tract cancer

“Drug costs in the US, $/per cycle” (opens the source at this quote in a new tab)

DrugBaseline cost in the United States, USD per cycle
Gemcitabine“15.06”
Cisplatin“8.72”
Durvalumab“11,730”
Oxaliplatin“26.76”
Calcium folinate“52.48”
Fluorouracil“18.57”
Irinotecan“35.88”
Capecitabine“180.6”
Regorafenib“21,546”
Ex-factory drug acquisition cost inputs for second-line regimens in cholangiocarcinoma from an Italian perspective

“The costs of drugs are ex-factory, obtained from Italian Medicine Agency (AIFA) public determinations and are expressed in euros (€). The dosage of drugs was considered according to those reported in the phase III RCTs.” (opens the source at this quote in a new tab)

“We have assumed the following costs (value added tax excluded): ivosidenib (blister of 30 tables) = 13 800 € [5], 5-fluorouracil (5-FU) = 3.81 € (1 g/20 mL, 1 vial) [6], folinic acid (FA) = 33.13 € (1 vial = 100 mg) [7], oxaliplatin = 136.74 € (5 mg/mL concentrate for solution for infusion, 1 glass vial of 10 mL) [8].” (opens the source at this quote in a new tab)

Real-world United States cost per patient per month by line of therapy in advanced biliary tract cancer

“The mean PPPM costs for the overall population were $18,274 for all-cause costs, of which approximately 84% ($15,296) comprised BTC-related costs. The total mean (SD) PPPM all-cause costs by LOT were $19,589 ($22,603) for 1LOT, $22,617 ($19,302) for 2LOT and $33,534 ($40,588) for 3LOT.” (opens the source at this quote in a new tab)

“We found that total all-cause PPPM cost was $19,589 during 1LOT, increasing to $22,617 and $33,534 as the treatment advanced to 2LOT and 3LOT, respectively, with >80% of PPPM costs only related to BTC.” (opens the source at this quote in a new tab)

Real-world United States cost per patient per month after failure of first-line therapy for advanced cholangiocarcinoma

“Total mean per patient per month CCA-related healthcare costs were $7,743, with medical services ($6,685) a larger driver of monthly costs relative to treatment costs ($1,058).” (opens the source at this quote in a new tab)

“The total mean all-cause PPPM healthcare costs were $14,403.” (opens the source at this quote in a new tab)

Real-world United States cost per patient per month among patients treated with pemigatinib

“CUP was associated with significantly higher prevalence of metastatic disease (100.0% vs 63.6%), per patient per month (PPPM) ambulatory HCRU (8.2 vs 5.5), and ambulatory costs ($8584 vs $5308).” (opens the source at this quote in a new tab)

“Medical costs averaged $13 444 vs $9881 PPPM for CUP and non-CUP, respectively” (opens the source at this quote in a new tab)

Modelled lifetime treatment costs per patient in advanced biliary tract cancer from a United States payer perspective

“In China and the US, the cost of pembrolizumab plus chemotherapy was higher than that of chemotherapy alone ($85,480 versus $21,616, $297,282 versus $156,281).” (opens the source at this quote in a new tab)

Administration and monitoring cost assumptions for FOLFOX, the principal second-line comparator

“the committee concluded that the model should include a relative dose intensity of 78% for FOLFOX, and that relative dose intensity should be applied to both treatment acquisition and administration costs.” (opens the source at this quote in a new tab)

“At the second meeting, the company updated its model to include the NHS cost collection reference cost for all ECGs. This was £118. The EAG noted that this may be an overestimate and instead chose to use the cost for directly accessed diagnostic services only (£54).” (opens the source at this quote in a new tab)

Companion diagnostic or biomarker testing cost for tovecimig

No evidence found.

Biomarker testing cost assumptions for biomarker-selected second-line comparators

“The clinical experts described that the cancer is screened for different genetic alterations at diagnosis to determine eligibility for targeted second-line treatment.” (opens the source at this quote in a new tab)

“The costs of additional IHC tests were included as part of the company submission.” (opens the source at this quote in a new tab)

“To the present costs we should add the cost of the IDH1 analysis (about 190 € for each patient [18]), that should be performed for all cholangiocarcinoma, with IDH1 mutation in approximately 20% of patients with intrahepatic cholangiocarcinoma [1]” (opens the source at this quote in a new tab)

United States cost of liposomal irinotecan with fluorouracil and leucovorin in second-line biliary tract cancer

No evidence found.